Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: TG-C Clear all
Completed Phase 3 Interventional Results available

Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

NCT00549848
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine, Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

NCT02883049
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
Interventions
Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
5,949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 10, 2026, 3:33 AM EDT
Recruiting Phase 2 Interventional

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

NCT06124157
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine
Procedure · Biological · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
366 Days to 46 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
141
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00002744
View directory record Official record
Conditions
Leukemia
Interventions
asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, prednisone, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
1,970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
31
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia

NCT00003671
View directory record Official record
Conditions
Leukemia
Interventions
asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, thioguanine, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
50
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 10, 2026, 3:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

NCT00439296
View directory record Official record
Conditions
Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia, Refractory Pediatric ALL
Interventions
ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Cyclophosphamide, 6-thioguanine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
Up to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Children With Lymphoma

NCT00002590
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, pegaspargase, prednisone, thioguanine, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2007
U.S. locations
30
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00002798
View directory record Official record
Conditions
Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
asparaginase, daunorubicin hydrochloride, fludarabine phosphate, therapeutic hydrocortisone, allogeneic bone marrow transplantation, 3-dimensional conformal radiation therapy, filgrastim, cytarabine, idarubicin, dexamethasone, thioguanine, etoposide, methotrexate, cyclophosphamide, aldesleukin, busulfan
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 10, 2026, 3:33 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

NCT02112916
View directory record Official record
Conditions
Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma, Ann Arbor Stage III Childhood Lymphoblastic Lymphoma, Ann Arbor Stage IV Adult Lymphoblastic Lymphoma, Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma, Childhood T Acute Lymphoblastic Leukemia
Interventions
Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Radiation Therapy, Thioguanine, Vincristine, Vincristine Sulfate
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
188
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 143 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

NCT00002812
View directory record Official record
Conditions
Leukemia
Interventions
asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, idarubicin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
2,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
32
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2013 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Not applicable Interventional

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00016302
View directory record Official record
Conditions
T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
prednisone, vincristine sulfate, daunorubicin hydrochloride, asparaginase, methotrexate, cyclophosphamide, cytarabine, mercaptopurine, leucovorin calcium, dexamethasone, doxorubicin hydrochloride, thioguanine, radiation therapy, nelarabine, pegaspargase, pharmacological study, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

NCT00671034
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Calaspargase Pegol-mknl, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Pharmacological Study, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 30 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 1 Interventional Results available

Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)

NCT00866307
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Prophylactic Cranial Irradiation, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 10, 2026, 3:33 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

NCT03914625
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Interventions
Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Mercaptopurine Oral Suspension, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
365 Days to 31 Years
Enrollment
6,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
201
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

NCT00408005
View directory record Official record
Conditions
T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions
Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
1,895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
191
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

NCT01190930
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Quality-of-Life Assessment, Questionnaire Administration, Thioguanine, Vincristine Sulfate
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
9,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
213
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 10, 2026, 3:33 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

NCT06317662
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 365 Days
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
113
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT00369317
View directory record Official record
Conditions
Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
asparaginase, daunorubicin hydrochloride, cytarabine, thioguanine, etoposide, laboratory biomarker analysis
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 4 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
88
States / cities
Phoenix, Arizona • Downey, California • Long Beach, California + 73 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 10, 2026, 3:33 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

NCT03203330
View directory record Official record
Conditions
Degenerative Osteoarthritis
Interventions
TG-C, Placebo Control
Biological
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
40 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 10, 2026, 3:33 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

BATokines as Biomarkers of Brown Fat in Humans

NCT05050240
View directory record Official record
Conditions
Healthy Lifestyle
Interventions
Cooling Vest Procedure, Fasting overnight
Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 28 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 10, 2026, 3:33 AM EDT
Active, not recruiting Phase 3 Interventional

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT03007147
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
184
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 10, 2026, 3:33 AM EDT
Recruiting Phase 3 Interventional

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

NCT03959085
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 25 Years
Enrollment
5,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
203
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 10, 2026, 3:33 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

NCT02101853
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Pharmacological Study, Radiation Therapy, Therapeutic Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
166
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 135 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 10, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee

NCT01221441
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
TissueGene-C, Normal Saline
Biological · Drug
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Pinellas Park, Florida • Baltimore, Maryland • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Sep 10, 2026, 3:33 AM EDT